drugset

drugset / Trial / NCT03899857

Pembrolizumab for Newly Diagnosed Glioblastoma

NCT03899857 ↗

Phase 2 Active not recruiting 56 enrolled University of Zurich Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

The study explores the addition of pembrolizumab to temozolomide-based radiotherapy in patients with newly diagnosed glioblastoma.

Timeline

Start: 2020-10-21
Primary completion: 2026-04-30
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pembrolizumab	Monoclonal antibody	200 mg	—

Indications